NCT05848154 - Application of ctDNA in Evaluation of Neoadjuvant Chemotherapy Efficacy and Exploration of Chemoresistance Mechanisms in Pancreatic Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 1, 2023

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions

Patients With Non-metastatic Pancreatic CancerEvaluation of Tumor Resectability Shall be Made in Consensus at Multidisciplinary Meetings, According to NCCN Guideline Version 1.2022 Pancreatic Adenocarcinoma

Interventions

DIAGNOSTIC_TEST

ctDNA detection

Blood samples are collected from patients at different time points during the monitoring process before treatment, after treatment, after surgery, and after adjuvant therapy/chemotherapy. ctDNA detection is performed on blood samples of all enrolled patients. WES and RNA-seq of samples from patients before and after treatment are performed to reveal the mechanisms of drug resistance.

Trial Locations (1)

200000

Zhongshan Hospital, Shanghai